摘要
目的比较吡格列酮或格列美脲联合二甲双胍治疗2型糖尿病(T2DM)患者的疗效与安全性。方法选取我院2013年2月—2017年1月收治的T2DM患者140例,随机分为A组(吡格列酮+二甲双胍)和B组(格列美脲+二甲双胍),两组均治疗3个月,对比两组治疗效果。结果治疗后,两组空腹血糖、餐后2 h血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数均下降,胰岛素敏感指数上升,两组间比较,差异无统计学意义(P>0.05)。B组BMI、血糖达标时间、低血糖发生率均低于A组(P<0.05)。结论格列美脲或吡格列酮联合二甲双胍治疗T2DM疗效相近,但格列美脲联合二甲双胍体对重控制更优,血糖达标时间更短,低血糖发生率更低。
Objective To compare the effects of pioglitazone and Glimepiride for type 2 diabetes mellitus（T2DM） clinical efficacy and safety of patients. Methods 140 cases of T2DM patients admitted to our hospital from February 2013 to January 2017 were selected, they were randomly divided into group A（pioglitazone plus metformin） and group B（glimepiride plus metformin）, the two groups were treated for 3 months, and the treatment effect was compared between the two groups. Results After treatment, fasting blood glucose, postprandial 2 h blood glucose, glycosylated hemoglobin, fasting insulin and insulin resistance index of the two groups decreased, and the insulin sensitivity index increased. There was no significant difference between the two groups（P〈0.05）. The incidence of BMI, blood glucose level and hypoglycemia in group B were lower than that in group A（P〈0.05）. Conclusion Glimepiride or pioglitazone combined with metformin in the treatment of T2DM curative effect is similar, but the body weight of glimepiride combined with metformin in better control of blood glucose, shorter time, lower incidence of hypoglycemia.
作者
魏占玲
WEI Zhanling(Internal Medicine Department, The First Social Welfare Institute in Beijing, Beijing 100069, China)
出处
《中国继续医学教育》
2018年第2期134-136,共3页
China Continuing Medical Education
